Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development ; volume:9 ; number:1 ; day:9 ; month:3 ; year:2024 ; pages:1-21 ; date:12.2024
npj vaccines ; 9, Heft 1 (9.3.2024), 1-21, 12.2024
- Urheber
-
Chugh, Saurabh
Bahal, Ritika Kar
Dhiman, Rohan
Singh, Ramandeep
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-024-00834-y
- URN
-
urn:nbn:de:101:1-2405122116258.410155420606
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chugh, Saurabh
- Bahal, Ritika Kar
- Dhiman, Rohan
- Singh, Ramandeep
- SpringerLink (Online service)
Ähnliche Objekte (12)
Design of liposomes for the delivery of antigens for a vaccine against tuberculosis
Advancing preclinical cancer models to assess clinically relevant outcomes
Vaccine design via antigen reorientation
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
Vaccine against tuberculosis: what’s new?
P19-36. Preclinical study of CombiHIVvac vaccine
Advancing preclinical models of psychiatric disorders with human brain organoid cultures
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis
Computer aided selection of candidate vaccine antigens
Design of liposomes for the delivery of antigens for a vaccine against tuberculosis
Advancing preclinical cancer models to assess clinically relevant outcomes
Vaccine design via antigen reorientation
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
Vaccine against tuberculosis: what’s new?
P19-36. Preclinical study of CombiHIVvac vaccine
Advancing preclinical models of psychiatric disorders with human brain organoid cultures
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis
Computer aided selection of candidate vaccine antigens
Design of liposomes for the delivery of antigens for a vaccine against tuberculosis
Advancing preclinical cancer models to assess clinically relevant outcomes
Vaccine design via antigen reorientation
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
Vaccine against tuberculosis: what’s new?
P19-36. Preclinical study of CombiHIVvac vaccine
Advancing preclinical models of psychiatric disorders with human brain organoid cultures
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis